Clinical trial
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or…
NCT00314353 · NSABP Foundation Inc, Other · Terminated
Key facts
| NCT number | NCT00314353 |
|---|---|
| Title | Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon |
| Official title | Randomized Phase II Clinical Trial of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Line Treatment for Metastatic Colorectal Cancer |
| Lead sponsor | NSABP Foundation Inc, Other |
| Collaborators | Genentech, Inc. Industry Hoffmann-La Roche International Drug Development Institute |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasms |
| Intervention type | Drug |
| Interventions | Bevacizumab, Oxaliplatin, Capecitabine, Irinotecan |
| Enrollment | 7 |
| Start date | Mar 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | Jun 1, 2010 |
| First posted | Apr 13, 2006 |
| Last update posted | Oct 6, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: